GenoMed Inc. (GMED)

[mingwan0]

The 10SB from 2002 contains some other interesting bits and pieces:

http://www.stocknight.com/news_images/GMED_10SB_5-02.pdf

Page 96 mentions the following in relation to the scientific timeline:

20K SNP chip--Asper?
lOOK SNP chip--Mergen?

Order samples from:
Russia (DWCC)
Italy (Hippocrates)
Miami (Gosser)--still requires visit
Korea (MyDNA)

Here are the two chip development companies:

http://www.asperbio.com/company.htm

http://www.mergen-ltd.com/index.htm

For the sample providers it is difficult to pin down Hippocrates, Gosser or MyDNA. DWCC was known as the DW Cordinating Center. It changes it's name to Evidence Clinical and Pharmaceutical Research (Evidence CPR):

http://www.evidence-cpr.com/ieo/index.html

Here is the original press release that talks about them:

GenoMed, Inc. finalizes Letter of Intent with DW Coordinating Center to acquire Caucasian Samples

January 18, 2002--GenoMed Inc.--("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED), a St. Louis, Missouri based medical genomics biotechnology company, announced today that it has signed a Letter of Intent with DW Coordinating Center (DWCC; website: www.dwccenter.com) to acquire Caucasian samples for fifty common, serious diseases. DWCC is a global contract research organization with operations in Russia and Eastern Europe. DWCC will obtain blood samples from patients with common diseases, such as high blood pressure, heart attack, stroke, and various cancers. DWCC uses FDA approved practices of sample collection, including informed patient consent, and has a sophisticated quality control system. DWCC has conducted clinical research since 1989 for pharmaceutical and biotechnology companies, and for research institutes, including Aventis, Glaxo SmithKline, Pfizer, CV Therapeutics, and the National Institutes of Health. Since 1989, DWCC has recruited over 19,000 patients for clinical trials. Dr. David Moskowitz, Chairman and Chief Medical Officer of GenoMed, stated, "First and foremost we are very pleased to have established this relationship with DWCC. I am confident that the Company's relationships with organizations such as DWCC will provide the Company with the samples that it needs to generate a tremendous amount of disease gene data from a variety of ethnic groups. Over the next 12-24 months, the Company will score millions of genotypes from these samples and work diligently to identify the associations within each specific ethnic group that cause these serious diseases. Obviously, we believe that this data will be of substantial importance to the healthcare industry, and be a valuable asset to the Company from a business standpoint."